论文部分内容阅读
米托蒽醌(NO)和大剂量阿糖胞苷(AC)联合(NOAC)对难治性非何杰金淋巴瘤(NHL)疗效较好,但有较强的骨髓抑制等毒副作用。本研究旨在确定重组人粒-巨噬细胞集落刺激因子(rhGM-CSF)对NOAC治疗NHL时的毒副作用和疗效的影响。病例收集自9个研究中心,共37例,均为成人难治性NHL。其中5个中心的23例在NOAC方案后加
Mitoxantrone (NO) and high dose of cytarabine (ACAC) combined (NOAC) are effective in the treatment of refractory non-Hodgkin’s lymphoma (NHL), but have strong bone marrow suppression and other side effects. The purpose of this study was to determine the effect of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) on the toxic side effects and therapeutic effects of NOAC on NHL. The cases were collected from 9 research centers, a total of 37 cases, all adult refractory NHL. Twenty-three of the five centers were added after the NOAC program